Metabolism

MASH / NASH Mouse Models

Biocytogen has developed multiple metabolic dysfunction–associated steatohepatitis (MASH) mouse models, formerly known as nonalcoholic steatohepatitis (NASH) mouse models, to support preclinical MASH/NASH research and liver disease drug evaluation. Available models include the Gubra-Amylin (GAN) diet–induced MASH/NASH mouse model, GAN + CCL4–induced model, high-fat methionine choline–deficient (HFMCD) model, and STAM MASH/NASH mouse model. These MASH/NASH models reproduce key pathological features of human metabolic liver disease, including hepatic steatosis, inflammation, and fibrosis, providing reliable in vivo platforms for studying disease mechanisms and evaluating anti-steatotic, anti-inflammatory, and anti-fibrotic therapeutics.
Nonalcoholic Steatohepatitis (NASH) Models

on this page

  • MASH/NASH Mouse Model Introduction
  • Results
  • Related Products
  • FAQs

Publication

    MASH/NASH Mouse Model Introduction

    Metabolic dysfunction–associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), is a progressive metabolic liver disease within the nonalcoholic fatty liver disease (NAFLD) spectrum. It is characterized by hepatic steatosis, inflammation, hepatocyte injury, and fibrosis, which can progress to cirrhosis or hepatocellular carcinoma. The co-existence of obesity, insulin resistance, and type II diabetes significantly increases the risk of disease onset and progression.

    Clinically, MASH involves steatohepatitis, hepatocyte ballooning, liver fibrosis, and metabolic dysfunction. To better understand disease mechanisms and evaluate new treatments, MASH/NASH mouse models are widely used in preclinical liver disease research. These include genetically modified, diet-induced, or a combination of the two.

    Biocytogen has established several validated models representing different stages of MASH pathogenesis, including:

    • CCl₄-induced MASH model, characterized by liver inflammation and fibrosis.
    • Gubra-Amylin (GAN) diet–induced MASH mouse model, showing obesity, glucose intolerance, and hepatic steatosis.
    • High-fat methionine–choline-deficient (HFMCD) diet–induced MASH model, producing severe hepatic injury and fibrosis.
    • STAM model, in which neonatal mice treated with streptozotocin (STZ) and fed a high-fat diet develop steatohepatitis, hyperglycemia, and metabolic dysfunction.

    These MASH/NASH models provide reliable in vivo platforms for mechanistic studies, drug efficacy testing, and preclinical research, advancing the discovery of anti-steatotic, anti-inflammatory, and anti-fibrotic therapies.

    Results

    GAN diet+CCL4 Induced NASH Mouse Model
    GAN diet+CCL4 Induced NASH Mouse Model

    MGL3196 and OCA alleviated NASH symptom in GAN diet+CCL4 induced NASH mouse model. A-B, ALT and AST levels of modeling and treatment group. C-F, TG, TC, HDL-C, LDL-C levels of modeling and treatment group. Data are expressed as mean ± SEM. N = 9 mice per group. *p<0.05, **p<0.01,***p<0.001.

    Resmetirom and OCA treatment alleviates symptoms of NASH
    Resmetirom and OCA treatment alleviates symptoms of NASH

    Resmetirom and OCA decreased NAS scores. A, Representative pictures of H&E staining showing degree of NASH. B, NAFLD activity score (NAS) assessed by an external expert pathologist. C-D, TG and TC content in liver after treatment. Data are expressed as mean ± SEM. N = 9-10 mice per group. *p<0.05, **p<0.01, ***p<0.001.

    Resmetirom and OCA treatment alleviates liver fibrosis
    Resmetirom and OCA treatment alleviates liver fibrosis

    Resmetirom and OCA treatment alleviates liver fibrosis. A, Representative pictures of Sirius Red staining showing degree of liver fibrosis (scare bar: 200μm). B, Liver fibrosis score was assessed according to Sirius Red staining. C, Representative pictures of IHC staining showing α-SMA expression (scare bar: 200μm).D, Quantitively data of α-SMA expression. Data are expressed as mean ± SEM. N = 9 mice per group. *p<0.05, **p<0.01,***p<0.001,****p<0.0001.

    Frequently Asked Questions (FAQs) About Nonalcoholic Steatohepatitis (NASH) Models

    1. What is MASH, and how is it related to NASH?

    Metabolic dysfunction-associated steatohepatitis (MASH), previously termed nonalcoholic steatohepatitis (NASH), is a progressive liver disease characterized by hepatic steatosis, inflammation, hepatocyte ballooning, and fibrosis. It is closely associated with obesity, insulin resistance, and type 2 diabetes. Advanced MASH can progress to cirrhosis or hepatocellular carcinoma (HCC). MASH mouse models provide valuable in vivo platforms for evaluating novel therapeutic candidates in preclinical drug development.

    2. What MASH mouse models does Biocytogen offer for preclinical research?

    Biocytogen provides a range of MASH/NASH mouse models developed using dietary interventions, chemical induction, or a combination of both to address different disease phenotypes and preclinical study objectives.
    Available MASH mouse models include:
    • GAN Diet (Gubra-Amylin NASH diet): Models obesity, dyslipidemia, hepatic steatosis, and MASH-related pathology. Available in wild-type C57BL/6, B-ob/ob, and aged mice.
    • GAN Diet + CCl₄ (Accelerated Fibrosis): Combines dietary and chemical induction to accelerate hepatic fibrosis development.
    • HFMCD (Rapid Fibrosis): Enables rapid evaluation of hepatic inflammation and fibrosis.
    • STAM (MASH-to-HCC Progression): Supports studies of liver disease progression toward hepatocellular carcinoma (HCC).

    3. How does the GAN diet-induced MASH model differ across mouse strains?

    GAN diet-induced MASH models exhibit distinct disease phenotypes and induction timelines depending on the mouse strain.
    • Wild-Type (WT) C57BL/6 Mice: Develop obesity, dyslipidemia, steatosis, inflammation, and hepatocyte ballooning. A representative efficacy study involves approximately 16 weeks of GAN diet induction followed by 4 weeks of dosing. More pronounced fibrosis generally requires 30 weeks or longer. Alternatively, combining the GAN diet with CCl₄ can accelerate fibrogenesis, shortening the induction period to approximately 14 weeks.
    • B-ob/ob Mice: Pre-existing metabolic abnormalities accelerate MASH development, resulting in pronounced inflammation, hepatocyte ballooning, and detectable fibrosis after approximately 12-16 weeks of GAN diet feeding.
    • Aged C57BL/6 Mice: Exhibit accelerated MASH development, with characteristic hepatic pathological changes typically emerging within 12-20 weeks.
    • Target-Humanized Mice: Biocytogen combines the GAN diet induction protocol with single- and multi-target humanized mice, such as GCGR/GIPR/GLP-1R triple-humanized mice (B-hGCGR/hGIPR/hGLP1R), DGAT2 humanized mice (B-hDGAT2), and CIDEB humanized mice (B-hCIDEB), to support target validation and efficacy evaluation across diverse therapeutic modalities.

    4. What readouts are evaluated in Biocytogen’s MASH mouse studies?

    Biocytogen’s preclinical pharmacology services incorporate histopathological, biochemical, and metabolic assessments to characterize MASH progression and evaluate therapeutic efficacy. Key readouts include:
    • Histopathological Assessment: H&E staining to assess hepatic steatosis, lobular inflammation, and hepatocyte ballooning, with disease activity evaluated using the NAFLD Activity Score (NAS).
    • Liver Fibrosis Assessment: Sirius Red staining to evaluate collagen deposition, complemented by immunohistochemistry (IHC) for fibrosis-associated markers such as α-SMA.
    • Serum Biochemistry: Liver injury markers (ALT and AST) and lipid parameters, including triglycerides (TG), total cholesterol (TC), HDL-C, and LDL-C.
    • Metabolic and Organ Parameters: Body weight, blood glucose, liver weight, liver index, and hepatic lipid content to assess metabolic status and treatment response.
    Additional readouts may be incorporated based on the therapeutic mechanism of action and study requirements.

    5. Why choose the HFMCD diet-induced MASH mouse model for rapid fibrosis studies?

    The high-fat, methionine- and choline-deficient (HFMCD) diet impairs very-low-density lipoprotein (VLDL) synthesis and secretion, disrupting hepatic lipid export and promoting lipid accumulation, inflammation, and fibrosis within approximately 4-8 weeks.
    The short induction period makes the HFMCD model particularly suitable for preclinical efficacy studies of anti-inflammatory and anti-fibrotic therapies. However, the model typically lacks the obesity-associated metabolic phenotype seen in human MASH, and circulating triglyceride and cholesterol levels may be reduced.

    6. What are the key characteristics of the STAM mouse model of MASH?

    The STAM mouse model combines neonatal streptozotocin (STZ) treatment with subsequent high-fat diet (HFD) feeding to induce hyperglycemia and progressive hepatic injury. STZ impairs insulin secretion, contributing to the model’s characteristic metabolic dysfunction.
    Key characteristics include:
    • Rapid Disease Induction: MASH-associated pathological changes can develop within approximately 6-9 weeks.
    • Metabolic Dysfunction: Hyperglycemia and impaired insulin secretion develop without the obesity phenotype typically observed in GAN diet-induced models.
    • Disease Progression: The model supports the investigation of hepatic inflammation, fibrosis, and progression to HCC at later stages.

    7. How can clients access Biocytogen’s MASH mouse models and preclinical services?

    Biocytogen offers two solutions to support MASH drug development:
    • Preclinical Products: Access off-the-shelf single- and multi-target humanized mouse models covering key MASH-related therapeutic targets for in-house studies.
    • Preclinical Services: Collaborate with Biocytogen’s pharmacology team on customized in vivo efficacy studies using established GAN diet-induced, GAN diet + CCl₄, HFMCD, and STAM models.
    These solutions support the preclinical evaluation of diverse therapeutic modalities, including antibodies, small molecules, peptides, and oligonucleotide-based therapeutics, with model selection and induction protocols tailored to the therapeutic target and mechanism of action.
    Contact Biocytogen to discuss humanized mouse model availability, ordering information, study design options, and quotations for your MASH drug development program.